Aegerion Pharma (AEGR) Tops Q4 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Jefferies Raises Aegerion Pharmaceuticals (AEGR) Target Price After Strong Brazilian Sales
May 5, 2015 10:20 AM EDTJefferies maintains their Hold rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) and decided to raise the target price to $26 (from $24) after about a 16% increase in Juxtapid sales. Sales numbers were driven by the 8.9% U.S. increase as well as some solid sales numbers in Brazil.... More
